Products
-
- BBB DamageCell Death and ApoptosisNeuroinflammationNeuronal Damage and RepairOxidative StressVascular Mechanisms
- 3D BBB Models
- Organ-on-a-Chip BBB ModelsTranswell Models3D BBB Models Culture Substrate
- 3D HydrogelsCollagensAnmial BBB ModelsCell Lines for BBB Modeling
- Immortalized CellsPrimary CellsStem Cells
Mouse Has3 ELISA Kit (AC3824)
Cat.#: ASET-2413
Specifications
Description Mouse Has3 ELISA Kit, a 90-minute assay kit, allows for the in vitro quantitative determination of mouse Has3 concentrations in serum, plasma, and other biological fluids. Size 96T Sample Type Serum, plasma or other biological fluids. Reactivity Mouse Unit 1 kit Packaging Kit of pre-coated 96 well microplates (12 x 8 well strips) Detection Type Colorimetric Assay Type Quantitative Sensitivity 9.31 ng/L Precision Intra-assay CV: < 8%
Inter-assay CV: < 10%Product Range 125-2000 ng/L Assay Time ~90 min Storage Store the unopened kit at +4°C. Shipping Wet ice Citation Guidance If you use our product in a scientific publication, please cite it as "Ace Therapeutics Cat.#". Click here to submit your paper's PubMed ID (PMID) to receive rewards. Related Products
Cat.# Name Assay Type Price ASET-2099 Mouse Neuroglobin ELISA Kit (AC3510) Quantitative inquiry ASET-2079 Mouse EGR2 ELISA Kit (AC3490) Quantitative inquiry ASET-1668 Rat SIRP alpha ELISA Kit (AC3079) Quantitative inquiry ASET-1043 Mouse Glypican 4 ELISA Kit (AC2454) Quantitative inquiry ASET-1752 Human Otx2 ELISA Kit (AC3163) Quantitative inquiry ASET-1149 Mouse Dynamin 1 ELISA Kit (AC2560) Quantitative inquiry ASET-1604 Rabbit IL-6 ELISA Kit (AC3015) Quantitative inquiry ASET-2015 Human Visfatin ELISA Kit (AC3426) Quantitative inquiry ASET-1655 Rat GDNF ELISA Kit (AC3066) Quantitative inquiry ASET-2056 Bovine Insulin ELISA Kit (AC3467) Quantitative inquiry All of our products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.
0Inquiry Basket